PE20120863A1 - 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdl - Google Patents
5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdlInfo
- Publication number
- PE20120863A1 PE20120863A1 PE2012000302A PE2012000302A PE20120863A1 PE 20120863 A1 PE20120863 A1 PE 20120863A1 PE 2012000302 A PE2012000302 A PE 2012000302A PE 2012000302 A PE2012000302 A PE 2012000302A PE 20120863 A1 PE20120863 A1 PE 20120863A1
- Authority
- PE
- Peru
- Prior art keywords
- trifluor
- nicotinamide
- dichloro
- hydroxy
- phenyl
- Prior art date
Links
- -1 3,4-DICHLORO-PHENYL Chemical class 0.000 title abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 229960003966 nicotinamide Drugs 0.000 title abstract 3
- 239000011570 nicotinamide Substances 0.000 title abstract 3
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical group OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 abstract 2
- GYXGGHPMGUITOT-DLBZAZTESA-N 5-(3,4-dichlorophenyl)-n-[(1s,2r)-2-hydroxycyclohexyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide Chemical compound O[C@@H]1CCCC[C@@H]1NC(=O)C1=CN=C(OCC(F)(F)F)C(C=2C=C(Cl)C(Cl)=CC=2)=C1 GYXGGHPMGUITOT-DLBZAZTESA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 150000002148 esters Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170097 | 2009-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120863A1 true PE20120863A1 (es) | 2012-07-23 |
Family
ID=42830122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000302A PE20120863A1 (es) | 2009-09-11 | 2010-09-08 | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdl |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8227491B2 (OSRAM) |
| EP (1) | EP2475645B1 (OSRAM) |
| JP (1) | JP5604520B2 (OSRAM) |
| KR (1) | KR101382871B1 (OSRAM) |
| CN (1) | CN102639506B (OSRAM) |
| AR (2) | AR078352A1 (OSRAM) |
| AU (1) | AU2010294277B2 (OSRAM) |
| BR (1) | BR112012005511B8 (OSRAM) |
| CA (1) | CA2771493C (OSRAM) |
| CL (1) | CL2012000611A1 (OSRAM) |
| CO (1) | CO6491033A2 (OSRAM) |
| CR (1) | CR20120089A (OSRAM) |
| CY (1) | CY1114377T1 (OSRAM) |
| DK (1) | DK2475645T3 (OSRAM) |
| EC (1) | ECSP12011723A (OSRAM) |
| ES (1) | ES2423821T3 (OSRAM) |
| HR (1) | HRP20130869T1 (OSRAM) |
| IL (1) | IL217920A (OSRAM) |
| IN (1) | IN2012DN00763A (OSRAM) |
| MA (1) | MA33563B1 (OSRAM) |
| MX (1) | MX2012002254A (OSRAM) |
| MY (1) | MY161103A (OSRAM) |
| NZ (1) | NZ597514A (OSRAM) |
| PE (1) | PE20120863A1 (OSRAM) |
| PL (1) | PL2475645T3 (OSRAM) |
| PT (1) | PT2475645E (OSRAM) |
| RS (1) | RS52987B (OSRAM) |
| RU (1) | RU2541475C2 (OSRAM) |
| SG (1) | SG179035A1 (OSRAM) |
| SI (1) | SI2475645T1 (OSRAM) |
| TW (1) | TWI412363B (OSRAM) |
| UA (1) | UA107088C2 (OSRAM) |
| WO (1) | WO2011029827A1 (OSRAM) |
| ZA (1) | ZA201201599B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US20120101282A1 (en) * | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| BRPI0609685A2 (pt) | 2005-04-06 | 2010-04-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos |
| RU2454405C2 (ru) * | 2006-10-04 | 2012-06-27 | Ф.Хоффманн-Ля Рош Аг | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина |
-
2010
- 2010-08-09 UA UAA201204339A patent/UA107088C2/ru unknown
- 2010-09-03 US US12/875,196 patent/US8227491B2/en active Active
- 2010-09-08 DK DK10749873.5T patent/DK2475645T3/da active
- 2010-09-08 MY MYPI2012001104A patent/MY161103A/en unknown
- 2010-09-08 SG SG2012016127A patent/SG179035A1/en unknown
- 2010-09-08 MX MX2012002254A patent/MX2012002254A/es active IP Right Grant
- 2010-09-08 CA CA2771493A patent/CA2771493C/en active Active
- 2010-09-08 BR BR112012005511A patent/BR112012005511B8/pt active IP Right Grant
- 2010-09-08 NZ NZ597514A patent/NZ597514A/xx unknown
- 2010-09-08 SI SI201030327T patent/SI2475645T1/sl unknown
- 2010-09-08 TW TW099130367A patent/TWI412363B/zh active
- 2010-09-08 ES ES10749873T patent/ES2423821T3/es active Active
- 2010-09-08 RU RU2012113924/04A patent/RU2541475C2/ru active
- 2010-09-08 PT PT107498735T patent/PT2475645E/pt unknown
- 2010-09-08 RS RS20130395A patent/RS52987B/sr unknown
- 2010-09-08 AU AU2010294277A patent/AU2010294277B2/en active Active
- 2010-09-08 WO PCT/EP2010/063136 patent/WO2011029827A1/en not_active Ceased
- 2010-09-08 KR KR1020127008704A patent/KR101382871B1/ko active Active
- 2010-09-08 JP JP2012528344A patent/JP5604520B2/ja active Active
- 2010-09-08 PL PL10749873T patent/PL2475645T3/pl unknown
- 2010-09-08 EP EP10749873.5A patent/EP2475645B1/en active Active
- 2010-09-08 HR HRP20130869AT patent/HRP20130869T1/hr unknown
- 2010-09-08 IN IN763DEN2012 patent/IN2012DN00763A/en unknown
- 2010-09-08 CN CN201080039932.7A patent/CN102639506B/zh active Active
- 2010-09-08 PE PE2012000302A patent/PE20120863A1/es active IP Right Grant
- 2010-09-09 AR ARP100103303A patent/AR078352A1/es not_active Application Discontinuation
-
2012
- 2012-01-12 CO CO12004250A patent/CO6491033A2/es active IP Right Grant
- 2012-02-02 IL IL217920A patent/IL217920A/en active IP Right Grant
- 2012-02-21 CR CR20120089A patent/CR20120089A/es unknown
- 2012-03-02 ZA ZA2012/01599A patent/ZA201201599B/en unknown
- 2012-03-03 EC ECSP12011723 patent/ECSP12011723A/es unknown
- 2012-03-05 MA MA34662A patent/MA33563B1/fr unknown
- 2012-03-08 CL CL2012000611A patent/CL2012000611A1/es unknown
-
2013
- 2013-09-05 CY CY20131100768T patent/CY1114377T1/el unknown
-
2018
- 2018-11-16 AR ARP180103371A patent/AR114032A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140065A1 (es) | Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico y procesos para su elaboracion | |
| EA201590653A1 (ru) | Терапевтическое средство при дислипидемии | |
| PE20211544A1 (es) | Derivados de pirimidiniloxi benceno como herbicidas | |
| UY32848A (es) | Compuestos heterocíclicos de oxima | |
| DOP2014000086A (es) | Inhibidor de cetp de oxazolidinona bicíclico fusionado | |
| GT201300153A (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina | |
| EA200702541A1 (ru) | Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты | |
| CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| TR201909777T4 (tr) | Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar | |
| EA201500574A1 (ru) | Новые инданилоксидигидробензофуранилуксусные кислоты | |
| BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
| CY1123456T1 (el) | Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων | |
| EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
| ECSP10010433A (es) | Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas | |
| PE20140245A1 (es) | Compuesto de furo[3,2-d]pirimidina | |
| CL2012000937A1 (es) | Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad. | |
| CL2013000417A1 (es) | Compuestos derivados de heteroarilos sustituidos y sus sales, como inhibidores de p13k; composicion farmaceutica que los comprende, util para tratar trastornos proliferativos, trastornos inflamatorios o cardiovasculares. | |
| CL2016001023A1 (es) | Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2. | |
| SV2012004235A (es) | Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CL2008000089A1 (es) | Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios. | |
| DK2318007T3 (da) | Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler | |
| CL2016001172A1 (es) | Nuevos inhibidores de dgat2. | |
| CL2014000441A1 (es) | Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer. | |
| CL2015000614A1 (es) | Compuesto 2-((4-benzo[d]tiazol-5-ilamino)-6-(terc-butilsulfonil)quinazolin-7-il)oxi)etilo, sus sales o hidratos, inhibidor de rip2 cinasa; compuestos cristalinos; composicion farmaceutica; uso en el tratamiento de enfermedad de crohn, colitis ulcerosa y sindrome de blau. | |
| AU2014362144A2 (en) | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |